



Challenging Case Studies in Laboratory Diagnosis: A focus on anemia

Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP
President, Fitzgerald Health Education Associates, Inc.,
North Andover, MA
Family Nurse Practitioner, Adjunct Faculty, Family Practice Residency
Greater Lawrence (MA) Family Health Center
Editorial Board Member
The Nurse Practitioner Journal, Prescriber's Letter, American Nurse Today

© 2010 Fitzgerald Health Education Associates, Inc.

1



Anemia defined

- A complex of signs and symptoms characterized by decreases in numbers of RBCs or Hb content caused by blood loss, deficient erythropoiesis, excessive hemolysis, or a combination of these changes.

© 2010 Fitzgerald Health Education Associates, Inc.

2



When does anemia occur?

- With insult severe enough
 - Disturb normal homeostatic mechanisms
 - Exceed reserves


© 2010 Fitzgerald Health Education Associates, Inc.

3



Normal erythropoiesis

A decrease in oxygen tension of the renal blood perfusion serves as a signal to the kidney to begin producing EPO



© 2010 Fitzgerald Health Education Associates, Inc.


4

Adapted from Schott et al. *US Pharmacist*, 1997;22:HS5-HS12



RBC Development

Stem cells, upon exposure to erythropoietin, proliferate and differentiate to form red blood cells



JH Brock et al., *Iron Metabolism in Health and Disease*, London, England: W.B. Saunders Co; 1994

5



Conditions needed for RBC formation

Functional erythropoietin mechanism	Erythropoietin source= 90% renal, 10% hepatic. Erythropoietin supply diminished in renal failure (Typically GFR < 49 mL/ min)
Uncompromised DNA synthesis	DNA synthesis impaired by presence of chronic inflammation such as found in infection, autoimmune disorders including systemic lupus erythematosus, rheumatoid arthritis.

© 2010 Fitzgerald Health Education Associates, Inc.

6



Conditions needed for RBC formation

Hemoglobin synthesis unimpaired by lack of iron, vitamin or globin production	Adequate nutrition (iron, B vitamins, vitamin C, protein, others) and absorption
-------------------------------------------------------------------------------	----------------------------------------------------------------------------------



Conditions needed for RBC formation

Intact marrow micro-environment	<p>Revealed in the production of reticulocytes, young RBCs that contain residual RNA. In health= 1-2% of TRBC.</p> <p>The reticulocyte count reflects ability of bone marrow to produce RBCs.</p> <p>Anticipated response in anemia= Reticulocytosis.</p> <p>Absence of reticulocytosis or reticulocytopenia= Inadequate bone marrow response</p>
---------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Causes of anemia

- Blood loss
 - Acute from hemorrhage
 - In adult >1 liter before drop in hemoglobin
 - Most likely cause of sudden, dangerous drop in hct
 - Chronic from erosive gastritis, heavy menses, GI malignancy
 - Iron from RBC wasted via blood loss cannot be recycled



Causes of decreased RBC counts

- Reduced RBC production
 - Nutritional (vitamin B12, folic acid, iron deficiency), anemia of chronic disease (ACD), bone marrow suppression
- Premature destruction
 - Hemolysis, shortened lifespan (<90 d, NL RBC lifespan= 90-120 d)




Laboratory evaluation of the person with suspected anemia



What are H and H, RBC?

Are these values proportionally decreased?

- Hemoglobin to hematocrit ratio= 1:3
 - 10 g= 30%
 - 12 g= 36%
 - 15 g= 45%





What is the cell size?

Wintrobe's classification

- Mean corpuscle volume (MCV)
 - Microcytic (small cell)
 - MCV < 80 fl
 - Normocytic (normal size cell)
 - MCV 80-96 fl
 - Macrocytic (Abnormally large cell)
 - MCV > 96 fl


© 2010 Fitzgerald Health Education Associates, Inc.

13



What is the cell's hemoglobin content?

- Reflected by mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC)



© 2010 Fitzgerald Health Education Associates, Inc.

14



What is the cell's hemoglobin content?



- Hemoglobin= color
- Color= chromic
 - Normochromic= Normal color
 - MCHC = 31- 37 g/dL
 - Hypochromic= Pale
 - MCHC < 31 g/dL

© 2010 Fitzgerald Health Education Associates, Inc.

15



Hypochromic vs. normochromic



© 2010 Fitzgerald Health Education Associates, Inc.

16



What is the RDW (RBC volume distribution width)?



- An index of variation in RBC size
 - RDW NL= 11.5-15%, significant report >15%
 - Quantitative report of anisocytosis
 - New cells differ in size when compared to older cells
- One of the most reliable markers of deficient erythropoiesis in evolving macro/ microcytic anemia

© 2010 Fitzgerald Health Education Associates, Inc.

17



Elevated RDW vs. NL RDW



© 2010 Fitzgerald Health Education Associates, Inc.

18



What is the reticulocyte count?

- Is the body able/ attempting to correct the anemia?
- In health
 - 0.5-1.5% of TRBCs
- NL response in anemia
 - Reticulocytosis (>1.5%)
 - Since retic MCV > 96 fl, marked reticulocytosis = Elevated RDW



Reticulocyte count

Per Ferri, one of the most helpful tests in evaluating person with anemia

- Usually elevated
 - Hemolytic anemia, hemorrhage, with anemia therapy (folate, B12, iron therapy as needed and directed by underlying disease process)



Reticulocyte count

Per Ferri, one of the most helpful tests in evaluating person with anemia

- Usually decreased
 - Aplastic anemia, bone marrow suppression, chemotherapeutic agents, anemia of chronic disease



Lab assessment in anemia

- What is the RPI?
 - Reticulocyte production index
 - <2 = Inadequate response
 - >3 = Adequate response



Corrected retic ct, RPI

- Retic% corrected
 - Retic% reported X (pt's hct)/45
- RPI
 - Retic% corrected / Correction factor



RPI

How fast do RBC mature?

Patient's hct (%)	Correction factor
40-45	1.0
35-39	1.5
25-34	2.0
15-24	2.5
<15	3.0



Reticulocyte production index calculator

<http://cpsc.acponline.org/enhancements/227rpiCalc.html>



42 yo woman with an CU-IUD

- Heavy menses for the past 5 years
- CC= Fatigue, decreased exercise tolerance X 3 months
- Concomitant hx
 - Gastric bypass > 10 years ago (BMI preop= 57, now 34)
 - HTN, on lisinopril with HCTZ



42 yo woman with an CU-IUD

Physical exam reveals pale conjunctiva and a grade II/VI systolic ejection murmur over the precordium without radiation.



42 yo woman with an CU-IUD

- Hg=6.6 g (12- 14 g) (660 g/L {120-140 g/L})
- Hct=21.4% (37- 45%) (.214 proportion {.37-.45 proportion})
- RBC= 2.7 mil (4.2-5.4 mil)
- WBC= 4,400 mm³ (6,000-10,000 mm³)
 - NL differential




42 yo woman with an CU-IUD

- MCV=65.5 fl (80- 96 fl)
 - Mean corpuscle volume
- MCHC=30.5 g/dl (31- 37 g/dl) (305 g/L {310-370 g/L})
 - Mean corpuscle hemoglobin concentration
- MCH= 20 pg/cell (27-33)
 - Mean corpuscle hemoglobin



Hypochromic vs. normochromic






42 yo woman with an CU-IUD

- RDW=22.9% (11.5- 15%) (.229 proportion { .115-.15 proportion})
 - New cells differ in size when compared to older cells
 - Per Ferri, best indicator of evolving micro- or macrocytic anemia



Elevated RDW vs. NL RDW



RDW in IDA

- “This is reflected in the red blood cell distribution width (RDW); thus, the earliest evidence of the development of an iron-deficient erythropoiesis is seen in the peripheral smear and by an increased RDW.”

– Source- Conrad, M. Iron deficiency anemia, available at www.emedicine.com, accessed 4.29.10.



Mean Corpuscle Hemoglobin vs Mean Corpuscle Hemoglobin Concentration

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> • MCH <ul style="list-style-type: none"> – Average mass of hemoglobin per RBC | <ul style="list-style-type: none"> • MCHC <ul style="list-style-type: none"> – Measure of the concentration of hemoglobin in a given volume of packed RBC |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|



42 yo woman with an CU-IUD

- Reticulocytes
 - Reported= 5% (.05 proportion)
 - Retics (corrected)= 2.4% (.024 proportion)




42 yo woman with an CU-IUD

- RBC Morphology
 - 3+ hypo (pale)
 - 1+ aniso
 - Anisocytosis= Varied size
 - Marked poik
 - Poikilocytosis= Varied shape



Aniso, poik



42 yo woman with an CU-IUD

- Platelets= 670,000 mm³
 - Reactive or clonal?
 - Evidence of previous elevation?
 - Splenomegaly?
 - Evidence of source (profound anemia, infection, inflammation)



42 yo woman with an CU-IUD

- Ferritin= 2 ng/ml (10- 322) (4.5 pmol/L {22.47-723.53 pmol/L})
 - Highly sensitive and specificity
- Iron= 75 ug/dl (30- 160) (13.4 umol/L {5.37-28.64 umol/L})
 - Lower sensitivity and specificity
 - Why WNL?



42 yo woman with an CU-IUD

- TIBC= 479 ug/ dl (228- 428) (85.7 umol/L {40.8-76.6 umol/L})
 - Lower sensitivity and specificity



42 yo woman with an CU-IUD

- Vitamin B12= 121 pg/ml (180-914) (89.3 pmol/L {132.8-674.5 pmol/L})
 - Dietary source?
 - Contributor to low levels?
 - Does this contribute to marked microcytosis?



Order of change in IDA

- | | |
|------------------------------------------|-------------------------------|
| • Ferritin ↓ | • TIBC ↑ |
| – Iron stores | – Open spots for iron to bind |
| • Marrow ↓ | • Hb, hct ↓ |
| – Most sens, spec test but seldom needed | • Indices ↓ |
| • Serum iron ↓ | – Small, pale cells |
| – Drug level | |
| • RDW ↑ | |
| – New cells are smaller, paler | |



Vitamin B12 replacement: True or False?

- Traditionally, doses of vitamin B12 (cobalamin) 1000 mcg per injection have been used. A cobalamin dose of more than 100 mcg in a single injection exceeds the binding capacity of transcobalamin II, however; the excess is excreted via the kidney and wasted.

© 2010 Fitzgerald Health Education Associates, Inc.

43



Vitamin B12 supplementation options

- Vitamin B₁₂ nasal gel
 - Weekly at a dose of 500 mcg
- Vitamin B12 oral tablets
 - 1000 mcg daily
- Cobalamin injection
 - 100 -1000 mcg monthly

© 2010 Fitzgerald Health Education Associates, Inc.

44



Same patient also mentions...

- New onset restless legs over p 6 months
 - Could this be attributable to IDA?

© 2010 Fitzgerald Health Education Associates, Inc.

45



Iron deficiency anemia Most common form of anemia worldwide

- “It is important economically because it diminishes the capability of individuals who are affected to perform physical labor, and it diminishes both growth and learning in children.”

– Source- Conrad, M. Iron deficiency anemia, available at www.emedicine.com, accessed 4.30.10.

© 2010 Fitzgerald Health Education Associates, Inc.

46



IDA tx= Fe plus B complex with C

- Iron forms
 - Oral forms
 - Ferrous sulfate
 - Ferrous gluconate
 - Enteric coated Fe
 - Parenteral Fe

© 2010 Fitzgerald Health Education Associates, Inc.

47



Treatment of IDA

- Advise with oral Fe
 - Possible chelation effect
 - Spacing of doses
- How long should you treat?
 - Correct Hb plus at least 2 months
- What about routine Fe supplementation?

© 2010 Fitzgerald Health Education Associates, Inc.

48



Anticipated results with IDA treatment

- Reflects marrow response
 - Reticulocytes peak @ 6 d
- If not actively losing blood
 - Hg increase at 2 g/ q 3 weeks
 - Hct increase q 6% q 3 weeks
- Stores replenished
 - NL ferritin at 3-6 months after hg to norm



Example 32 year-old woman who is taking phenytoin


- Hg= 12 g (12-14 g)
 - 120 g/L (120-140 g/L)
- Hct= 37% (36-43%)
 - .37 proportion (.36-.43 proportion)
- RBC= 4.2 million (4.2-5.4 mil)
- MCV= 105.5 fl (81-99 fl)
- MCH= 31 pg (27-33 pg)
- RDW= 12.8% (11.5-15%)
 - .128 proportion (.115-.15 proportion)



Macrocytosis

(MCV>96 fl, >102 fl in elder)

- Abnormally large cell (macrocytic) due to altered RNA:DNA ratio, hemoglobin content WNL (normochromic), new cells larger than old cells (elevated RDW)



Drug-induced macrocytosis usually without anemia

- Etiology
 - Use of select medications such as carbamazepine (Tegretol), zidovudine (AZT), valproic acid (Depakote), phenytoin (Dilantin), alcohol, others
 - Reversible when use of offending medication is discontinued



Drug-induced macrocytosis

- Abnormally large (macrocytic) cell due to altered RNA:DNA ratio, hemoglobin content WNL (normochromic), new cells usually same size as old cells (NL RDW)



Tamara

- 35 year-old woman who drinks 5-9 beers/d
- Hg=11.4 g (114 g/L)
 - Hct= 34.1% (.341 proportion)
 - MCV=103 fl
 - MCHC=32 g/dl
 - RDW= 18% (.18 proportion)
 - Reticulocytes
 - Reported=1.5% (.15 proportion)
 - Corrected= 1.95% (.195 proportion)
 - RPI=0.73



Tamara

- WBC- 3,200/ mm³
 - 5-10 K
- Neuts= 40%
 - 50-70%
- Lymph= 55%
 - 24-44%
- Plts= 96K
 - 130-400K



Macrocytic anemia evaluation

- Degree of macrocytosis typically in proportion to degree of anemia
- Serum folate= 10 ng/mL (3-20 ng/ml)
 - “Drug” level, reflects dietary intake over p 48-72 h
- Vitamin B12= 398 pg/mL (NL= 180-914 pg/mL)



Tamara

- RBC folate= 160 ng/ml (NL= 280-790 ng/ml)
 - Incorporated in erythrocytes during cell development, remain unchanged throughout RBC lifespan (90-120 d), not influenced by diet
 - Potentially falsely elevated in person with rapidly developing folate deficiency
 - Also low in about 50% who have vit B12 (cobalamin) deficiency



FAD risks

- Inadequate dietary intake
 - Elders, alcoholics, impoverished
- Decreased ability to absorb folic acid
 - Malabsorption syndromes such as sprue and celiac disease
- High demand state
 - Lactation (due to transfer to milk)



FAD risks

- When cell division is high
 - Pregnancy
 - Childhood growth spurts
 - Hemolytic anemia
 - Inflammation



FAD risks

- In select at-risk populations
 - Fish tapeworm infestation
 - Potent risk for IDA, FAD, PA
 - Dietary FAD less common in women than in past due to FA added to wheat flour



Treatment FAD anemia

- Modify underlying cause
- Folic acid supplementation
 - 0.5 mg/day to 1 mg/day to 5 mg/day, with the usual dose being 1 mg/day



Treatment FAD anemia

- Counsel about diet
 - Most fruits, vegetables rich in folic acid
 - In particular, asparagus, broccoli, spinach, lettuce, lemons, bananas, melons, liver, and mushrooms
- Overcooking food destroys most of folic acid content.



Response to folic acid therapy

- Bone marrow response
 - Reticulocytosis=7-10 d into therapy
- If not actively losing blood
 - Hct rises by 4-5%/ wk
- Leukopenia, thrombocytopenia
 - Resolve within 2- 3 d tx



If dx in question

- B12, folate
 - Critical to intracellular biochemical reactions
- Deficiency leads to buildup of substrates
 - Homocysteine (5.1-13.9 uM, FAD)
 - Methylmalonic acid (MMA) (73-271 u, PA)



You advise a person who is a vegan to supplement the diet with:

- A. Vitamin A.
- B. Iron.
- C. Vitamin B12.
- D. Folic acid.



66 yo woman presents

- 6 mo hx
 - Increasing fatigue
 - Worsening numbness of hands and feet
- Health history
 - Type 2 DM, dyslipidemia, HTN, all at treatment goal



66 yo woman presents

- Current medications (daily doses)
 - Metformin 2 g
 - Gliperimide 4 mg
 - Atorvastatin 20 mg
 - ASA 81 mg
 - Lisinopril 20 mg
 - HCTZ 12.5 mg



66 yo woman presents

- Hg= 11.2 g/ dl (12-14 g)
 - 112 g/L (120-140 g/L)
- Hct= 33% (36-43%)
 - .33 proportion (.36-.43 proportion)
 - 1: ratio with NL hydration
- RBC= 3.2 million (4.2-5.4 mil)
 - Proportionally decreased when compared with H & H



66 yo woman presents

- MCV= 112 fl (81-96 fl)
 - Does RBC size or color change over cell's life span?
- MCHC= 34.8 g/dL (31-37 g/dL)
 - What is the RBC lifespan?
- RDW= 19% (11.5-15%)
 - .19 proportion (.115-.15 proportion)
 - New cells different size (likely larger) when compared to old cells



Macrocytic anemia evaluation True or false?



- Degree of macrocytosis is typically in proportion to degree of anemia.
- Vitamin B12 and folate deficiency are causes of macrocytic anemia.



66 yo woman presents

- Cobalamin=100 pg/mL (190-914 pg/ml)
- Serum folate=8 ng/mL (3-20 ng/ml)
 - "Drug" level, reflects dietary intake over p 48-72 h



66 yo woman presents

- RBC folate = 380 ng/ml (NL= 280-790 ng/ml)
 - Incorporated in erythrocytes during cell development, remain unchanged throughout RBC lifespan (90-120 d), not influenced by diet



66 yo woman presents (continued)

- Potentially falsely elevated in person with rapidly developing folate deficiency
 - Also low in about 50% who have vit B12 (cobalamin) deficiency



Now what?



Vitamin B12 deficiency and metformin use

- Dose dependent response
 - Each 1 g/day metformin increment nearly triple vitamin B12 deficiency risk (odds ratio: 2.88; 95% CI, 2.2-3.9, $P < 0.001$)
 - Ting R Z-W, Szeto CC, Chan M H-M, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-9



Vitamin B12 deficiency and metformin use

- Time dependent response
 - On metformin for ≥ 3 y had 2 X risk compared with those using the drug for less than three years (odds ratio: 2.4; 95% CI, 1.5-3.9, $P = 0.001$)
 - Ting R Z-W, Szeto CC, Chan M H-M, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-9



Vitamin B12 deficiency and metformin use

- Particular risk in vegetarians
 - Adjusted risk of developing vitamin B12 deficiency vegetarians who use metformin = 1600%
 - Ting R Z-W, Szeto CC, Chan M H-M, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-9



Vitamin B12 deficiency and metformin use (continued)

- Advice with metformin use
 - Monitor for vitamin B12 deficiency
 - Vitamin B12 and B complex supplementation
 - Ting R Z-W, Szeto CC, Chan M H-M, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-9



72 yo woman with
HTN, dyslipidemia,
rheumatoid arthritis

- Medications
 - Lisinopril 20 mg qd
 - Atorvastatin 20 mg qd
 - Methotrexate 17.5 mg weekly
- Presents with 2-d hx new onset fatigue and shortness of breath on exertion



She was seen about 6 weeks ago...

- ... And had a normal hemogram and basic metabolic profile.
- About 10 days ago she was successfully treated for a UTI.
- PE today is non contributory other than a hemic murmur and conjunctival pallor.



Today's labs

- Hg= 8.8 g/ dl (12-14 g)
 - .88 g/L (120-140 g/L)
- Hct= 23% (36-43%)
 - .23 proportion (.36-.43 proportion)
- RBC= 2.3 million (4.2-5.4 mil)
- MCV= 89 fl (81-96 fl)
- MCHC= 34.8 g/dL (31-37 g/dL)
- RDW= 12% (11.5-15%)
 - .12 (.115-.15 proportion)



Today's labs

- WBC= 2,800 mm³
 - N= 30%
 - L= 60%
 - M= 5%
- Platelets= 60,000 mm³



Her abnormal laboratory results
today are most likely due to:

- A. The interaction between the methotrexate and the recently prescribed antibiotic.
- B. The impact of the UTI on her overall health.
- C. A hemolytic reaction.
- D. Another cause not mentioned here.



How much will...

- ..the H and H drop in 1 week if no new RBCs are produced?
- In the absence of bleeding, how much increase in H and H should you anticipate with transfusion of 1 unit RBC?



References (continued)

- Ferri, F. (2009) *Ferri's Best Test: A practical guide to clinical laboratory medicine and diagnostic imaging* (2d. ed). Philadelphia: Elsevier Mosby, available at www.fhea.biz



References (continued)

- Desai, S. (2009) *Clinician's Guide to Laboratory Medicine: Pocket*, Houston, TX: MD2B, available at www.fhea.biz.



References (continued)

- Fitzgerald, M. A. (2010) *Hematologic and Immunologic*. In *Nurse Practitioner Certification Examination and Practice Preparation, 3d Edition*. Philadelphia, PA: F.A. Davis Company, available at www.fhea.biz



References

- Fitzgerald, M. (2007) *Laboratory Data Interpretation: A case study approach* (audioprogram), available at www.fhea.biz
- Fitzgerald, M. A. (2004) *Hematologic Disorders*. In Youngkin, E., Sawin, K., Kissinger, J., Israel, D. *Pharmacotherapeutics: A Primary Care Clinical Guide (2nd ed)*. Upper Saddle River, NJ: Prentice Hall.



End of Presentation!

Thank you for your time and attention.

Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP
www.fhea.com, e-mail: cs@fhea.com